Annexon, Inc. is seeking a BLA submission for neuroinflammatory disease and expects POC data for its oral C1 inhibitor.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Annexon, Inc. is seeking a BLA submission for neuroinflammatory disease and expects POC data for its oral C1 inhibitor.